Form 4: Coeptis Therapeutics Holdings VP of Operations, Daniel Yerace, Receives Stock Options

Daniel Alexander Yerace, VP of Operations at Coeptis Therapeutics Holdings, Inc., reports the acquisition of 5,000 non-qualified stock options on March 4, 2025.

Summary

• Daniel Alexander Yerace, the VP of Operations at Coeptis Therapeutics Holdings, Inc., filed a Form 4 on March 6, 2025.
• The report details the grant of 5,000 non-qualified stock options under the 2022 equity incentive plan on March 4, 2025.
• The exercise price of these options is equal to the company's stock price on the Nasdaq Capital Market on the grant date.
• The options vest over four years in equal quarterly installments, with the final vesting date on December 31, 2028.
• The options expire ten years from the grant date.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. It's a positive for the executive but doesn't necessarily indicate a significant shift in the company's prospects.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the VP of Operations.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of 4 years with quarterly installments are common among comparable companies.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the VP of Operations.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates